Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.hoc.2014.02.007 http://scihub22266oqcxt.onion/10.1016/j.hoc.2014.02.007 C4116747!4116747 !24880940     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\24880940 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Hematol+Oncol+Clin+North+Am 2014 ; 28 (3 ): 437-53 Nephropedia Template TP {{tp|p=24880940 |t=2014. Understanding the biology of melanoma and therapeutic implications |pdf=|usr=}}{{24880940 }} gab.com Text Understanding the biology of melanoma and therapeutic implications JO: Hematol Oncol Clin North Am http://www.kidney.de/pget.php?&tw=1&pmid=24880940 #FOAvip From 1976 to 2010, only 2 medications were approved for treating metastatic melanoma. Between 2011 and 2013, 4 agents were approved and other therapies have shown great promise in clinical trials. Fundamental discoveries, such as the identification of oncogenic mutations in most melanomas, the elucidation of the molecular signaling resulting from these mutations, and the revelation that several cell surface molecules serve as regulators of immune activation, have been instrumental in this progress. This article summarizes the molecular pathogenesis of melanoma, describes the current efforts to target oncogene-driven signaling, and presents the rationale for combining immune and molecular targeting. Twit Text FOAVip Understanding the biology of melanoma and therapeutic implications ????Hematol Oncol Clin North Am http://www.kidney.de/pget.php?&tw=1&pmid=24880940 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=24880940 #FOAvip English Wikipedia <ref>{{Cite pmid|24880940 }}</ref> Understanding the biology of melanoma and therapeutic implications #MMPMID24880940 Sullivan RJ ; Fisher DE Hematol Oncol Clin North Am 2014[Jun]; 28 (3 ): 437-53 PMID24880940 show ga From 1976 to 2010, only 2 medications were approved for treating metastatic melanoma. Between 2011 and 2013, 4 agents were approved and other therapies have shown great promise in clinical trials. Fundamental discoveries, such as the identification of oncogenic mutations in most melanomas, the elucidation of the molecular signaling resulting from these mutations, and the revelation that several cell surface molecules serve as regulators of immune activation, have been instrumental in this progress. This article summarizes the molecular pathogenesis of melanoma, describes the current efforts to target oncogene-driven signaling, and presents the rationale for combining immune and molecular targeting. |Genetic Predisposition to Disease/genetics [MESH] |Humans [MESH] |Melanoma/*drug therapy/genetics [MESH] |Models, Genetic [MESH] |Molecular Targeted Therapy/*methods/trends [MESH] |Mutation [MESH] |Proto-Oncogene Proteins/genetics [MESH] |Signal Transduction/*drug effects/genetics [MESH]Understanding the biology of melanoma and therapeutic implications (epmc).pdf DeepDyve Pubget Overpricing